Friday, November 19, 2021 6:52:03 AM
6:11 am ET November 19, 2021 (Dow Jones) Print
By Colin Kellaher
Gracell Biotechnologies Inc. on Friday said the U.S. Food and Drug Administration granted orphan-drug designation to GC012F, its lead product candidate, for the treatment of the blood cancer multiple myeloma.
The Shanghai clinical-stage biopharmaceutical company said GC012F has shown fast, deep and durable responses in patients with relapsed/refractory multiple myeloma in an ongoing study in China.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing-exclusivity period against competition.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
New York Yankees and Duke Basketball
Recent GRCL News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 03/04/2024 05:22:13 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/28/2024 05:15:31 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/26/2024 10:28:31 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/26/2024 10:28:02 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/26/2024 10:26:51 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/26/2024 10:26:40 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/22/2024 01:50:06 PM
- Gracell Biotechnologies Acquisition Completed • GlobeNewswire Inc. • 02/22/2024 01:45:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 01:22:08 PM
- Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement • GlobeNewswire Inc. • 02/20/2024 12:45:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:20:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 11:02:31 AM
- Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma • GlobeNewswire Inc. • 01/29/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 09:30:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 09:01:46 PM
- Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law Firm • PR Newswire (US) • 01/08/2024 03:06:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/26/2023 01:12:57 PM
- Gracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZeneca • Dow Jones News • 12/26/2023 11:44:00 AM
- AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion • Dow Jones News • 12/26/2023 08:05:00 AM
- AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases • Business Wire • 12/26/2023 07:01:00 AM
- Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases • GlobeNewswire Inc. • 12/26/2023 07:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 11:03:06 AM
- Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus • GlobeNewswire Inc. • 12/21/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/18/2023 09:00:48 PM
- Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 • GlobeNewswire Inc. • 12/12/2023 12:30:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM